The objective of this clinical trial is to assess the effectiveness of acetic acid in patients suffering from chronic cutaneous ulcers with biofilm. The primary question it seeks to address is whether acetic acid (as a 2% topical solution) is superior to the current standard treatment for chronic cutaneous ulcers with biofilm at our center (Prontosan®).
Participants will be randomly assigned to receive either the acetic acid solution treatment or the standard current treatment.

Start Date01 Sep 2024

Sponsor / Collaborator-

IRCT20240804062634N1 / RecruitingPhase 2IIT

Investigating the effect of herbal shampoo containing Gharaghorot, vinegar and ajwain on head lice: a clinical trial study

Start Date22 Aug 2024

Sponsor / Collaborator-

NCT06525870 / Enrolling by invitationPhase 2IIT

Efficacy of Topical 85%Trichloroacetic Acid in the Treatment of Low-grade Squamous Intraepithelial Lesion (LSIL) After Low-grade Abnormality of Screening Test: a Randomized Controlled Trial

To determine the efficacy and HPV clearance of an application of 85% TCA compared to placebo in the treatment of LSIL. This is a randomized, single-blind, placebo-controlled study in 44 women aged 18-65 years with histologic-proved HPV/CIN1. The study will test whether 85% TCA application will be effective treatment in LSIL. The clinical study hypothesis is that TCA application at cervical lesion and transformation zone will achieve histologic complete remission of LSIL in significantly more patients than placebo therapy. Patients will be randomized to placebo (3% acetic acid) or 85%TCA topical application at cervical lesion and transformation zone. After 3 months, cytology, colposcopy, histology, and HPV testing will be performed. The primary endpoint is treatment efficacy defined as complete histologic remission at 3 months after treatment. The secondary endpoint is HPV clearance 3 months after treatment. The protocol for the project is approved by an Institutional Review Board (IRB). Project is totally supported by a grant from Rajavithi Hospital. There is no external funding.

Start Date01 Aug 2024

Sponsor / Collaborator

Rajavithi Hospital

100 Clinical Results associated with Acetic Acid, Glacial

100 Translational Medicine associated with Acetic Acid, Glacial

100 Patents (Medical) associated with Acetic Acid, Glacial

2,376

Literatures (Medical) associated with Acetic Acid, Glacial

01 Jan 2025·Biomaterials Advances

Simultaneous viscoelasticity and sprayability in antimicrobial acetic acid-alginate fluid gels

Article

Author: Geoghegan, Joan A ; Robinson, Thomas E ; Grover, Liam M. ; Schofield, Zoe ; Moakes, Richard J.A. ; Moakes, Richard J A ; Robinson, Thomas E. ; Clark, Callum ; Grover, Liam M ; Moiemen, Naiem ; Geoghegan, Joan A.

Acetic acid is a promising alternative to antibiotics for topical applications, particularly burn wounds, however its site specificity and retention are impaired by poor material properties. In this study, acetic acid was investigated as both the gelling agent and antimicrobial active in alginate fluid gels. The formed microstructure was found to be directly dependent on acetic acid concentration, leading to highly tuneable material properties. At clinically relevant concentrations of 2.5-5 % acetic acid, the fluid gels were elastically dominated at rest, with viscosities up to 7 orders of magnitude greater than acetic acid alone. These material properties imparted long term surface retention and microparticle barrier function, not seen with either acetic acid or alginate solutions. Most notably, sprayability was enhanced simultaneously with the increased viscosity and elasticity due to the introduction of a discretised microstructure, leading to a remarkable tenfold increase in spray coverage. Formulation was found not to inhibit antimicrobial activity, despite the less acidic pH, with common burn wound pathogens Staphylococcus aureus and Pseudomonas aeruginosa being equally susceptible to the fluid gels as to acetic acid solutions.

31 Dec 2024·Gut Microbes

B. thetaiotaomicron -derived acetic acid modulate immune microenvironment and tumor growth in hepatocellular carcinoma

Article

Author: Ma, Hongbin ; Yang, Liang ; Yuan, Lei ; Liu, Fenghua ; Feng, Feiling ; Li, Yong ; Zhang, Rui ; Hu, Jinxiang ; Liang, Yingchao

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, and emerging evidence suggests that the gut microbiota may play a role in its development and progression. In this study, the association between B. thetaiotaomicron, a gut microbiota species, and HCC recurrence, as well as patient clinical outcomes, was investigated. It was observed that B. thetaiotaomicron-derived acetic acid has the potential to modulate the polarization of pro-pro-inflammatory macrophagess, which promotes the function of cytotoxic CD8+ T cells. The increased biosynthesis of fatty acids was implicated in the modulation of pro-inflammatory macrophages polarization by B. thetaiotaomicron-derived acetic acid. Furthermore, B. thetaiotaomicron-derived acetic acid was found to facilitate the transcription of ACC1, a key enzyme involved in fatty acid biosynthesis, through histone acetylation modification in the ACC1 promoter region. Curcumin, an acetylation modification inhibitor, significantly blocked the inhibitory effects of B. thetaiotaomicron and acetic acid on HCC tumor growth. These findings highlight the potential role of gut microbiota-derived acetic acid in HCC recurrence and patient clinical outcomes, and suggest a complex interplay between gut microbiota, immune modulation, fatty acid metabolism, and epigenetic regulation in the context of HCC development. Further research in this area may provide insights into novel strategies for HCC prevention and treatment by targeting the gut microbiota and its metabolites.

01 Dec 2024·Bioorganic Chemistry

Discovery of ent-kaurane diterpenoid glucosides as potent analgesics from the leaves of Pieris formosa

Article

Author: Zhang, Hanqi ; Wu, Yan ; Zheng, Guijuan ; Abudurexiti, Adila ; Yu, Jiaxing ; Feng, Yuanyuan ; Yao, Guangmin

To search for structurally novel analgesics from Ericaceae plants, the leaves of Pieris formosa collected at Yichang, Hubei, China, were phytochemically investigated for the first time. A total of fifteen ent-kaurane diterpene glucosides (1-15) including twelve new ones, named forminosides A-L (1-12), were isolated. Their structures were elucidated by comprehensive spectroscopic data analyses, quantum chemical calculations (¹³C NMR and ECD calculations and DP4+ analysis), and chemical methods. The absolute configures of 1-3, 5-8, 11, and 13 were further determined by single-crystal X-ray diffraction analysis. Forminoside A (1) represents the first 3α-(β-d-glucopyranosyloxy)-11,16-epoxy-ent-kaurane diterpenoid bearing a unique 12-oxa-pentacyclo[9.3.3.0^1,10.0^4,9.0^13,16]heptadecane core. Forminoside J (10) is the first 17-nor-ent-kaurane type diterpenoid from Ericaceae family, while forminoside L (12) represents the first example of 4,5-seco-ent-kaurane diterpenoid glycoside bearing an unusual α-hydroxyl-α,β-unsaturated ketone block. Notably, the structure of mollisside A was revised to 3β-(β-d-glucopyranosyloxy)-16β,17-dihydroxy-ent-kaurane based on the NMR and single-crystal X-ray diffraction data analysis of forminoside C (3). All the isolates 1-15 showed potent analgesic activity in the HOAc-induced writhing test in mice. Among them, compounds 1-3, 5-12, and 15 exhibited significant analgesic effects at a dose of 5.0 mg/kg with the inhibition rates over 50%. Compounds 1, 5, 7, and 9-12 still displayed significant analgesic effects with the inhibition rates exceeding 50% at a lower dose of 1.0 mg/kg. Forminosides J (10) and L (12) still showed significant analgesic potency even at a lower dose of 0.2 mg/kg, comparable to that of the positive control, morphine. This is first report of the analgesic activity of 11,16-epoxy-ent-kaurane diterpenoid. A preliminary structure-activity relationship was explored, providing new clues to design novel analgesics based on the ent-kaurane and related diterpenoids.

News (Medical) associated with Acetic Acid, Glacial

28 Aug 2024

·www.prnewswire.com

The Chemical Peel Market is projected to grow by USD 814.4 million from 2024 to 2028, driven by rising demand for aesthetic treatments and technological advancements, AI-powered report- Technavio

NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global chemical peel market size is estimated to grow by USD 814.4 millionn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.19% during the forecast period. Increasing demand for aesthetic procedures and technological advancement is driving market growth, with a trend towards increasing awareness about anti-aging measures. However, high cost of chemical peel products poses a challenge. Key market players include AbbVie Inc., AMOREPACIFIC Group Inc., Bausch Health Companies Inc., BeautyPharmaCo, Candela Corp., Caudalie International SE, Galderma SA, Hale Cosmeceuticals Inc, Image International Manufacturing LLC, Johnson and Johnson Services Inc., LOreal SA, MedPeel, Merz Pharma GmbH and Co KGaA, NEFTIS LABORATORIOS SL, Pierre Fabre SA, ProDerma Light, Radius Healthcare Pvt. Ltd., Renee Rouleau Inc., Topix Pharmaceuticals Inc., and Unilever PLC. Continue Reading Technavio has announced its latest market research report titled Global chemical peel market 2024-2028 Get a detailed analysis on regions, market segments, customer landscape, and companies - Click for the snapshot of this report Key Market Trends Fueling Growth The chemical peel market is experiencing significant growth due to the increasing awareness and demand for anti-aging procedures. In 2021 and 2022, there has been a rise in the number of cosmetic procedures performed in countries like the US, Brazil, Mexico, Germany, and Spain. This trend is driven by the advantages of chemical peels, including age spot reduction, sun damage removal, skin lightening, smoothening, and improved collagen growth. Vendors are actively promoting these benefits through various channels, such as websites, conferences, and magazine advertisements. Moreover, the increasing per capita income and economic development in emerging economies, particularly India and China, have led to a surge in online research and comparisons of various procedures. As a result, the chemical peel market is poised for continued growth during the forecast period. The Chemical Peel Market is witnessing significant growth due to the increasing demand for non-surgical skincare solutions. Trichloroacetic acid and Jessner's Solution are popular peeling agents used in chemical resurfacing for improving skin texture, reducing hyperpigmentation, acne scars, fine lines, and wrinkle reduction. These treatments are effective for sun damage, melasma treatment, and acne treatment. Medical aesthetics and cosmeceutical treatments using chemical formulations offer clinical benefits for various skin conditions. Glytone, Alpha hydroxy acid (AHA), sugar cane, sugar beets, lactic peel, milk, and Alpha-hydroxy acids (AHAs) are common peeling agents. Medium peels target the epidermis and dermis layers for enhanced skin health and beauty. The chemical peel procedure is a dermatologic treatment for skin health improvement and aesthetic enhancement. Discover a Comprehensive 360° Market Analysis: Understand the Impact of AI. For detailed information- Request Sample! Market Challenges The chemical peel market is currently facing a growth challenge due to the high cost of treatments, which is limiting its adoption, particularly in developing countries. The average price for a chemical peel ranges from USD600 to USD900, with significant variations depending on the type of peel. Light peels cost as low as USD150 but require multiple sessions for optimal results, while medium and deep peels can cost up to USD6,000. These high costs include fees for the chemical peel procedure, anesthesia, and operating room. The monopolistic approach of vendors, such as Allergan plc, in the market further contributes to the lack of competitive pricing. Allergan, a leading player in medical aesthetics, has acquired most of the market share, targeting high-income and upper-middle-class consumers. As a result, the inability of middle and lower-middle-class individuals to afford these costly procedures is hindering the growth of the global chemical peel market. The Chemical Peel market is thriving in the Skincare and Aesthetics industries, providing solutions for common concerns such as Acne, Pigmentation, and Wrinkle issues. Glytone's Peeling Solution, which contains Alpha Hydroxy Acids (AHAs) derived from Sugar Cane and Sugar Beets, is a popular choice for exfoliating the Epidermis. Medium Peels, using stronger Chemical Agents like TCA, reach deeper into the Dermis to address Acne spots, Dark Circles, and signs of Fatigue. Dermatology and Aesthetic Medicine professionals use these Dermatological Procedures for Skin Renewal, often combining different Chemical Compounds like Glycolic Acid, Lactic Acid, and Salicylic Acid for optimal results. The Beauty Industry continues to innovate with new Peeling Solutions, offering professional Chemical Exfoliation treatments for Facial Rejuvenation. For more insights on driver and challenges - Download a Sample Report Segment Overview This chemical peel market report extensively covers market segmentation by End-user 1.1 Hospital and recreation centers 1.2 Dermatology clinics Type 2.1 Light peel 2.2 Medium peel 2.3 Deep peel Geography 3.1 North America 3.2 Europe 3.3 APAC 3.4 South America 3.5 Middle East and Africa 1.1 Hospital and recreation centers- The Chemical Peel Market is experiencing steady growth due to increasing consumer awareness and demand for skin rejuvenation treatments. Businesses are offering various types of chemical peels to cater to diverse skin concerns, such as acne scars, aging, and sun damage. Market leaders are focusing on research and development to introduce innovative peel solutions and expand their customer base. Overall, the market is expected to continue its expansion in the coming years.For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 - 2022) - Download a Sample Report Research Analysis The Chemical Peel market encompasses a range of skincare treatments used in aesthetics to address various skin concerns, including acne, pigmentation, and wrinkle issues. These peels work by applying a chemical solution to the skin, causing it to exfoliate and peel off, revealing smoother, fresher skin. The solutions typically contain Alpha-hydroxy acids (AHAs) derived from fruits like glycolic acid from sugar cane and lactic peels from milk. Deeper peels may involve Phenol or Trichloroacetic acid, reaching the dermis for more significant results. Acne spots, dark circles, and signs of fatigue can also be targeted. Genetics and collagen production play a role in skin health, making chemical peels a popular choice for those seeking to improve their complexion in dermatology practices. Market Research Overview The Chemical Peel market encompasses a range of skincare treatments that utilize chemical solutions to improve the appearance of the skin. These peels are commonly used for various aesthetic concerns such as acne, pigmentation, and wrinkle issues. The solutions typically contain Alpha Hydroxy Acids (AHAs) derived from fruits like sugar cane and sugar beets, or Beta Hydroxy Acids (BHAs) like Salicylic Acid. The depth of the peel can vary from light to medium, affecting the epidermis or dermis layers. Chemical Peels are used to address acne spots, dark circles, fatigue, and signs of aging such as fine lines and wrinkles. The causes of these conditions can stem from genetics, sun damage, or lifestyle factors. The treatments promote collagen production, leading to skin renewal and texture improvement. Chemical Peels are considered a dermatological procedure and are also offered in aesthetic medicine clinics and the beauty industry. They provide a form of chemical exfoliation that goes beyond traditional cleansing methods. The solutions work by dissolving the bonds holding dead skin cells together, revealing smoother, healthier skin. Popular chemical peel formulations include Glytone, Jessner's Solution, TCA Peel, and various combinations of AHAs and BHAs. These treatments are administered as facial treatments in professional settings and are an essential part of medical aesthetics and cosmeceutical offerings. Chemical Peels contribute to skin health and beauty enhancement, addressing various skin conditions and concerns. They are an effective means of reducing hyperpigmentation, acne scars, sun damage, and melasma. The cosmetic procedure is a popular choice for individuals seeking wrinkle reduction and skin rejuvenation. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation End-user Hospital And Recreation Centers Dermatology Clinics Type Light Peel Medium Peel Deep Peel Geography North America Europe APAC South America Middle East And Africa 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

14 Mar 2024

·www.prnewswire.com

New Tuberculosis Test Could Improve TB Care Globally by Increasing Access to Testing in Low- and Middle-Income Countries

Findings Published in ADLM's Clinical Chemistry Journal WASHINGTON, March 14, 2024 /PRNewswire/ -- A new tuberculosis (TB) test disclosed in the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) Clinical Chemistry journal would allow testing for TB treatment monitoring to occur outside of a biosafety level 3 (BSL-3) laboratory. This could help reduce worldwide mortality from TB by enabling low- and middle-income countries that lack BSL-3 facilities to treat TB more efficiently. View the full study here: TB is the second leading infectious killer worldwide after COVID-19, and monitoring how the infection responds to treatment over time is a critical step in reducing mortality. However, because TB is highly infectious, patient samples can currently only be tested in BSL-3 laboratories, which contain resource-intensive features like directional air flow and incinerators that minimize the risk of contamination. This is a major hurdle to combatting TB globally, because approximately 80% of TB cases occur in low- and middle-income countries, many of which lack a BSL-3 laboratory. A team of researchers designed this test — called rapid enumeration and diagnostic for tuberculosis (READ-TB) — specifically to address lack of access to labs that meet BSL-3 requirements. This novel test determines how patients are responding to TB treatment. With READ-TB, sputum — thick mucus coughed up from the lungs — is treated with acetic acid, a chemical that kills bacteria but leaves bacterial RNA intact. A laboratory professional can then safely feed the RNA into a machine that measures RNA concentration, which is an indicator for how much Mycobacterium tuberculosis a patient is carrying and how the infection is responding to treatment. Compared to guanidium salts, the class of chemicals currently considered the gold standard for preserving RNA, acetic acid was more effective at killing sputum bacteria, doing so in just 30 minutes, which eliminates the need for a BSL-3 laboratory. Acetic acid was also just as effective as guanidium salts in preserving bacterial RNA. Notably, the researchers found that RNA was preserved in acetic acid for 14 days when kept at 25°C, and for at least 1 year when kept at –20°C. This is an important advantage for laboratories that lack –70°C freezers, which require a much greater amount of energy. Additionally, guanidium salts are toxic, while the concentration of acetic acid used for READ-TB is much safer to work with. Clinical trials for anti-TB drugs also stand to benefit from READ-TB. By providing a safe and efficient way to measure the concentration of TB RNA, it could enable researchers to compare the antibacterial strength and properties of drugs or combinations of drugs against one another. "We wanted to improve the assay for integration into diagnostic microbiology laboratories, for use in clinical trials, and to make it tenable in low- and middle-income countries, e.g., where no BSL-3 laboratory exists," the authors of the study write, referring to their earlier test. "READ-TB allows measurement of the molecular bacterial load to now be adopted by routine clinical microbiology laboratories for measuring M. tuberculosis bacterial load in sputum." About the Association for Diagnostics & Laboratory Medicine (ADLM) Dedicated to achieving better health through laboratory medicine, ADLM (formerly AACC) brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, ADLM has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit . Clinical Chemistry (clinchem.org) is the leading international journal of laboratory medicine, featuring nearly 400 peer-reviewed studies every year that help patients get accurate diagnoses and essential care. This vital research is advancing areas of healthcare ranging from genetic testing and drug monitoring to pediatrics and appropriate test utilization. CONTACT: Christine DeLong ADLM Senior Manager, Communications & PR (p) 202.835.8722 [email protected] Molly Polen ADLM Senior Director, Communications & PR (p) 202.420.7612 (c) 703.598.0472 [email protected] SOURCE Association for Diagnostics & Laboratory Medicine (ADLM)

Clinical Study

26 Jan 2024

·www.sciencedaily.com

Puffed-up MOFs for improved drug delivery

The spongelike structure of metal organic frameworks (MOFs) allows these polymers to possibly carry and deliver a range of therapeutic compounds. Now, researchers treated a chromium-containing MOF with a dose of acetic acid, more concentrated than in vinegar, to expand its pore size and surface area. The puffed-up MOFs held more ibuprofen or chemotherapy drug compared to the original version and had improved performance as a potential drug-delivery vehicle. The spongelike structure of metal organic frameworks (MOFs) allows these polymers to possibly carry and deliver a range of therapeutic compounds. Now, researchers reporting in ACS Applied Bio Materials treated a chromium-containing MOF with a dose of acetic acid, more concentrated than in vinegar, to expand its pore size and surface area. The puffed-up MOFs held more ibuprofen or chemotherapy drug compared to the original version and had improved performance as a potential drug-delivery vehicle. Taking medications by mouth is a convenient way to administer pharmaceuticals. However, this method sometimes involves ingesting several pills per day, or requires large pills that can be difficult to swallow. So, researchers are investigating how to use MOFs for drug delivery to minimize dosing frequency and maximize treatment efficiency. By customizing the polymers' pore sizes and structures, scientists have created nanoscale vehicles that may offer more controlled and targeted drug release. However, to carry and deliver even more drug molecules, the pores would need to expand further than current versions can. A research team led by Fateme Rezaei at the University of Miami wanted to optimize an existing MOF and improve the polymer's delivery of two common therapeutics of different molecular sizes: the anti-inflammatory drug ibuprofen and a smaller compound 5-fluorouracil, a chemotherapy drug used to treat cancer. They started with an established method to synthesize a biocompatible chromium-containing MOF and added a step with an acetic acid rinse. The acid caused the polymer's pores to expand from about 2.5 nanometers (nm) to 5 nm wide. In laboratory experiments to characterize the MOF's drug-loading capability, the researchers observed that the puffed-up version took in more ibuprofen and 5-fluorouracil molecules than the chromium-containing framework with standard-sized pores. Then, in drug-delivery experiments, they loaded the pore-expanded and standard MOFs with either ibuprofen or 5-flurouracil and measured how quickly the drugs passed into a saline solution. Rezaei and colleagues found that the new frameworks released both drugs substantially faster than the original ones. The researchers attributed the higher drug loading and release rates to the larger pores and surface area of the expanded framework, which provides larger "doors" for the drug molecules to enter and exit through. Simple changes such as these could maximize the effectiveness of MOFs in future drug-delivery applications, the researchers say. As a next step, they plan to determine how slow and progressive drug release within specified time frames can be achieved by modifying MOF pore structure. The authors acknowledge funding from the U.S. National Science Foundation.

100 Deals associated with Acetic Acid, Glacial

External Link

KEGG	Wiki	ATC	Drug Bank
D00010	Acetic Acid, Glacial	S02AA10 G01AD02	DB03166

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Contraception	Phase 2	CN	Shanghai New Asiatic Pharmaceutical Minhang Co. Ltd.	03 Jun 2024
Contraception	Phase 2	CN	Shanghai Institute of Biomedical Technology	03 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EADV2023	Not Applicable	Alopecia Areata	40	Trichloroacetic Acid 35%	vfroyskgwn(pzcedijfse) = uodmzehscl oadzagqkwh (vgykezezeo )	Positive	11 Oct 2023
EADV2022	Not Applicable	Cicatrix	30	Trichloroacetic acid	jsmytevaxn(npurefcwej) = cghtoinbop ohjigovthz (dapnbniuaz )	-	07 Sep 2022
TECAIN (IAS2021)	Not Applicable	Anal intraepithelial neoplasia	155	topical trichloroacetic acid (Electrocautery)	fzjcjkxohi(orzjbqoghe) = pouqtnfije nwrwejywrb (ckzkobcnrj )	-	01 Jan 2021
				Topical trichloroacetic acid	fzjcjkxohi(orzjbqoghe) = gkxkyqptyg nwrwejywrb (ckzkobcnrj )
NCT02614703 (CTgov)	Phase 2/3	Barrett Esophagus	60	Chromoendoscopy using Acetic Acid 2.5% (Chromoendoscopy Using Acetic Acid 2.5%)	rihxcfjabv(xshfnniabv) = qzprjzgbow ygdbpqrozw (pescbbeqcp, alclqxahsy - wiljmziwws) View more	-	26 Aug 2019
				Standard random esophageal biopsies (Standard Random Esophageal Biopsies)	rihxcfjabv(xshfnniabv) = rjbeghyxkn ygdbpqrozw (pescbbeqcp, hdrmyejyby - rsmjglbjdm) View more
ISN WCN2019	Not Applicable	Peritoneal Diseases	-	Acetic acid (2%)	gexvupebub(bavkfqtzat) = vvknfppyvt xqernnadnk (surbqyjkma, 44.4)	-	01 Jul 2019
				Mupirocin	gexvupebub(bavkfqtzat) = sbhnkabbjm xqernnadnk (surbqyjkma, 37.1)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis